---
document_datetime: 2025-06-19 11:32:36
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jetrea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: jetrea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.5082578
conversion_datetime: 2025-12-25 06:30:52.337901
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

<!-- image -->

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0053              | A.7 - Administrative change - Deletion of manufacturing sites | 11/12/2020                                  |                                             | Annex II and PL                  |           |
| IB/0052              | C.I.7.a - Deletion of - a pharmaceutical form                 | 06/11/2020                                  |                                             | SmPC, Labelling and              |           |

EMA/48166/2021 JETREA Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            | PL                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| T/0051              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/08/2020 | 15/09/2020 | SmPC, Labelling and PL            |
| II/0050             | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                 | 16/07/2020 | n/a        | longer authorised                 |
| PSUSA/10122 /201910 | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/05/2020 | n/a        | PRAC Recommendation - maintenance |
| IB/0048             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                     | 23/03/2020 | n/a no     |                                   |
| PSUSA/10122 /201810 | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/05/2019 | n/a        | PRAC Recommendation - maintenance |
| II/0042/G           | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal product | 14/02/2019 | n/a        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0046/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | 13/02/2019   | n/a           |                                  |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|----------------------------------|
| N/0044      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                | 08/01/2019   | 31/07/2019    | PL longer                        |
| IAIN/0043/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release product                                                                | 27/09/2018   | 31/07/2019 no | SmPC, Annex II, Labelling and PL |
| IAIN/0041   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                              | 07/08/2018   | n/a           |                                  |
| IB/0040/G   | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol Medicinal                                                                                | 30/07/2018   | 31/07/2019    | SmPC, Labelling and PL           |

<div style=\"page-break-after: always\"></div>

|                     | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                              |            |               |                               |                                                                                                                                                                                                                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0039              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                     | 29/05/2018 | 31/07/2019    | PL                            | authorised                                                                                                                                                                                                                                                           |
| PSUSA/10122 /201710 | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                            | 17/05/2018 | n/a           |                               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| IB/0037             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                         | 04/01/2018 | n/a           |                               |                                                                                                                                                                                                                                                                      |
| R/0033              | Renewal of the marketing authorisation.                                                                                                                                                                              | 12/10/2017 | 08/12/2017 no | SmPC, Labelling and PL longer | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of JETREA in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0036             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate product | 28/11/2017 | n/a           |                               |                                                                                                                                                                                                                                                                      |
| PSUSA/10122 /201704 | Periodic Safety Update EU Single assessment - ocriplasmin Medicinal                                                                                                                                                  | 26/10/2017 | n/a           |                               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| N/0035              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                     | 02/08/2017 | 13/10/2017    | PL                            |                                                                                                                                                                                                                                                                      |
| PSUSA/10122 /201610 | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                            | 05/05/2017 | n/a           |                               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| N/0032              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/02/2017   | 13/10/2017    | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026             | Update of sections 4.4, 4.8 and 5.1 of the SmPC to reflect new long-term safety and efficacy data based on the final CSR for study TG-MV-014 in fulfilment of the post-authorisation measure MEA 002. The SmPC updates also address PRAC recommendations in conclusion to PSUR 6 (EMEA/H/C/PSUSA/00010122/201510). The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the annexes, to align the annexes with the latest QRD templates (v9.1 and 10) and to update the contact details of the local representative in Spain in the Package Leaflet. An updated RMP version 7b was agreed during the procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product | 10/11/2016   | 13/10/2017 no | SmPC, Annex II and PL | The clinical efficacy and safety of JETREA for the treatment of vitreomacular traction (VMT) was assessed in 3 double- masked studies. For information on the design and main results of study TG-MV-014 please refer to section 5.1 of the Summary of Product Characteristics. Over 1400 patients have been treated with the recommended dose of 0.125 mg of JETREA in interventional clinical studies. All adverse reactions were ocular. The most commonly reported adverse reactions were vitreous floaters, eye pain, photopsia and chromatopsia as well as conjunctival haemorrhage resulting from the injection procedure. The most clinically relevant adverse reactions included blindness transient, retinal tear, retinal detachment, lens subluxation and macular hole progression. For further information, please refer to section 4.8 of the Summary of Product Characteristics. Ophthalmological examinations may be abnormal following the administration of JETREA. These include optical coherence tomography (OCT), ophthalmoscopy (foveal reflex), colour vision test (Roth 28-hue) and full-field ERG. This should be taken into consideration when using these tests for the diagnosis or monitoring of other conditions. longer authorised |
| PSUSA/10122 /201604 | Periodic Safety Update EU Single assessment - ocriplasmin Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/10/2016   | n/a           |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0030             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/08/2016   | n/a           |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10122 /201510   | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/05/2016   | n/a    | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|-------------------------------------|
| IB/0028/G             | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number product | 20/04/2016   | n/a no | longer authorised                   |
| IB/0027               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/04/2016   | n/a    |                                     |
| IA/0025               | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/02/2016   | n/a    |                                     |
| IB/0023/G             | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/01/2016   | n/a    |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                             |            |            |                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10122 /201504 | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                                                                                                                                   | 06/11/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10122 /201410 | Periodic Safety Update EU Single assessment - ocriplasmin                                                                                                                                                                                                                                                                   | 21/05/2015 | 17/07/2015 | SmPC and PL                      | Please refer to Jetrea PSUSA-10122-201410 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0021             | B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number                                                                                                                                   | 02/06/2015 | n/a no     | longer                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| X/0013              | The Marketing Authorisation Holder (MAH), ThromboGenics NV, submitted to the European Medicines Agency (EMA) an application for a line extension for Jetrea to introduce a formulation with adjusted fill volume for Jetrea 0.375 mg/0.3 mL Annex I_2.(d) Change or addition of a new pharmaceutical form Medicinal product | 26/02/2015 | 24/04/2015 | SmPC, Annex II, Labelling and PL | With this application, the (MAH) applied for a new pharmaceutical form and strength, Jetrea 0.375mg/0.3ml solution for injection, which no longer requires dilution prior to injection. The CHMP considered that the quality of Jetrea solution for injection was acceptable when used in accordance with the conditions defined in the product information. There was no new clinical or non-clinical data affecting the benefit-risk profile of Jetrea. However, there was a concern of possible medication errors upon introduction of the new formulation as the previously existing formulation (concentrate of solution for injection) requires dilution prior to injection, while the new formulation does not. Mix-ups between the two formulations could result in dilution errors and administration of inadequate doses. To mitigate this |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0016   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/10/2014   | 24/04/2015   | SmPC       | stability protocol   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|----------------------|
| IB/0017   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/09/2014   | n/a          | authorised |                      |
| IB/0015   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/08/2014   | n/a          | longer     |                      |
| II/0011/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation Medicinal product | 24/07/2014   | n/a no       |            |                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |               |                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|---------------------|
| IB/0012   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                      | 25/06/2014 | n/a           | longer authorised   |
| PSUV/0008 | Periodic Safety Update                                                                                                                                                                                                                                                                                                      | 08/05/2014 | n/a           | PRAC Recommendation |
| II/0007   | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                         | 20/03/2014 | 30/10/2014 no | SmPC and PL         |
| IA/0010   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information product                                                                                                                                      | 25/02/2014 | n/a           |                     |
| N/0009    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Medicinal                                                                                                                                                                                                                  | 13/02/2014 | 30/10/2014    | PL                  |
| IB/0006   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                      | 19/12/2013 | n/a           |                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0005     | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                         | 21/11/2013   | SmPC, Annex II and PL    |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------|
| IB/0003/G   | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 12/11/2013   | n/a no longer authorised |
| IAIN/0004/G | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing product                                        | 11/11/2013   | SmPC, Annex II and PL    |
| IAIN/0002   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal                                                                                                                                                                                                                                                                                           | 03/09/2013   | n/a                      |
| IAIN/0001   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                          | 10/06/2013   | n/a                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->